STEVENSON, Md.--(BUSINESS WIRE)--The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of LipoScience, Inc. (“LipoScience” or the “Company”) (Nasdaq: LPDX) relating to the proposed buyout of the Company by Laboratory Corporation of America Holdings (“LabCorp”).
On September 25, 2014 LipoScience and LabCorp announced the signing of a definitive merger agreement pursuant to which LabCorp will acquire LipoScience in a transaction valued at approximately $85.3 million. The transaction is expected to close in the fourth quarter of 2014, though LipoScience shareholders will most likely be asked to vote on the transaction well before that time.
Under the terms of the transaction, LipoScience shareholders are anticipated to receive $5.25 in cash for each share of LipoScience common stock they own. The firm’s investigation seeks to determine, among other things, whether the Company’s Board of Directors breached their fiduciary duties by failing to maximize shareholder value before agreeing to enter into the transaction, and whether LabCorp is underpaying for LipoScience shares.
If you currently own common stock of LipoScience and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at email@example.com or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.